정밀의료 시장 규모, 점유율 및 동향 분석 보고서 : 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Precision Medicine Market Summary

The global precision medicine market size was estimated at USD 116,575.36 million in 2025 and is projected to reach USD 405,106.04 million by 2033, growing at a CAGR of 16.99% from 2026 to 2033. The industry is characterized by a high degree of innovation and technological convergence, with advancements in genomics, molecular diagnostics, and data analytics playing a central role in shaping market evolution.

The integration of multi-omics data, clinical information, and real-world evidence is enabling a more comprehensive understanding of disease mechanisms and patient variability, supporting the development of highly targeted treatment strategies.

In addition, the increasing adoption of companion diagnostics and biomarker-based approaches is strengthening the integration between diagnostics and therapeutics, enabling more precise patient selection and improved treatment outcomes. The market is also witnessing significant strategic activity, including collaborations, partnerships, and acquisitions among biotechnology companies, pharmaceutical manufacturers, diagnostic providers, and technology firms aimed at expanding product portfolios, research capabilities, and geographic reach. Furthermore, evolving regulatory frameworks are supporting the development and commercialization of personalized therapies by establishing standards for safety, efficacy, and clinical validation of advanced diagnostic technologies.

The growing adoption of cloud computing, digital health platforms, and advanced bioinformatics solutions is further accelerating the growth of the industry. Healthcare providers, research institutions, and life sciences companies are increasingly leveraging integrated digital ecosystems to efficiently manage, analyze, and interpret large volumes of genomic and clinical data. The use of predictive modeling and advanced analytical tools is improving patient stratification, disease risk assessment, and therapy optimization, enabling more accurate and timely clinical decision-making. In addition, rising investments in precision oncology, rare disease therapeutics, and population genomics initiatives are supporting the development of individualized treatment pathways based on patient-specific genetic profiles. Expanding interoperability between healthcare systems, genomic databases, and digital diagnostic platforms is also improving data accessibility and clinical integration. As technological capabilities continue to advance and adoption increases across healthcare systems, the industry is expected to witness sustained expansion over the forecast period.

The industry is characterized by a high degree of innovation and technological convergence, with advancements in genomics, artificial intelligence, and data analytics playing a central role in shaping its evolution. The integration of multi-omics data, clinical information, and real-world evidence is enabling a more comprehensive understanding of disease pathways and patient variability. In addition, the increasing adoption of companion diagnostics and biomarker-based approaches is strengthening the linkage between diagnostics and therapeutics, allowing for more targeted treatment selection. The market is also witnessing strong strategic activity, including collaborations, partnerships, and acquisitions among biotechnology firms, pharmaceutical companies, and diagnostic providers to expand capabilities and geographic presence. Furthermore, regulatory frameworks are evolving to support the development and commercialization of personalized therapies, ensuring the safety, efficacy, and standardization of advanced diagnostic tools.

The growing adoption of cloud computing, digital health platforms, and advanced bioinformatics solutions is further accelerating the expansion of the industry. Healthcare providers and research organizations are increasingly leveraging integrated digital ecosystems to manage and interpret large volumes of genomic and clinical data more efficiently. The use of predictive analytics and machine learning algorithms is enhancing patient stratification, disease risk assessment, and therapy optimization, enabling more precise and timely clinical interventions. In addition, rising investments in precision oncology, rare disease research, and population genomics initiatives are supporting the development of customized treatment pathways tailored to individual genetic profiles. As interoperability between healthcare systems and genomic databases continues to improve, the ability to deliver scalable and data-driven personalized healthcare solutions is expected to strengthen significantly over the forecast period.

Global Precision Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global precision medicine market report based on application, end use, and region:

• Application Outlook (Revenue, USD Million; 2021 - 2033)
• Diagnostics
  • Genetic Tests
  • Direct to Consumer Tests
  • Esoteric Tests
  • Others
• Therapeutics
  • Pharmaceuticals
  • Oncology
  • Respiratory Diseases
  • Skin Diseases
  • CNS Disorders
  • Immunology
  • Genetic Diseases
  • Others
  • Medical Devices
  • Others
• End-use Outlook (Revenue, USD Million; 2021 - 2033)
• Home Care
• Hospitals
• Clinical Laboratories
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Kuwait
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Precision Medicine Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pricing Analysis

Chapter 4. Precision Medicine Market: Application Business Analysis

• 4.1. Application Market Share, 2025 & 2033
• 4.2. Application Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 4.4. Diagnostics
  • 4.4.1. Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.4.2. Genetic Testing
    • 4.4.2.1. Genetic Testing Market, 2021 - 2033 (USD Million)
  • 4.4.3. Direct to Consumer Tests
    • 4.4.3.1. Direct to Consumer Tests Market, 2021 - 2033 (USD Million)
  • 4.4.4. Esoteric Tests
    • 4.4.4.1. Esoteric Tests Market, 2021 - 2033 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market, 2021 - 2033 (USD Million)
• 4.5. Therapeutics
  • 4.5.1. Therapeutics Market, 2021 - 2033 (USD Million)
  • 4.5.2. Pharmaceuticals
    • 4.5.2.1. Pharmaceuticals Market, 2021 - 2033 (USD Million)
    • 4.5.2.2. Oncology
      • 4.5.2.2.1. Oncology Market, 2021 - 2033 (USD Million)
    • 4.5.2.3. Respiratory Disease
      • 4.5.2.3.1. Respiratory Disease Market, 2021 - 2033 (USD Million)
    • 4.5.2.4. Skin Disease
      • 4.5.2.4.1. Skin Disease Market, 2021 - 2033 (USD Million)
    • 4.5.2.5. CNS Disorders
      • 4.5.2.5.1. CNS Disorders Market, 2021 - 2033 (USD Million)
    • 4.5.2.6. Immunology
      • 4.5.2.6.1. Immunology Market, 2021 - 2033 (USD Million)
    • 4.5.2.7. Genetic Disease
      • 4.5.2.7.1. Genetic Disease Market, 2021 - 2033 (USD Million)
    • 4.5.2.8. Others
      • 4.5.2.8.1. Others Market, 2021 - 2033 (USD Million)
  • 4.5.3. Medical Devices
    • 4.5.3.1. Medical Devices Market, 2021 - 2033 (USD Million)
  • 4.5.4. Others
    • 4.5.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Precision Medicine Market: End Use Business Analysis

• 5.1. End Use Market Share, 2025 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End use, 2021 to 2033 (USD Million)
• 5.4. Home Care
  • 5.4.1. Home Care Market, 2021 - 2033 (USD Million)
• 5.5. Hospitals
  • 5.5.1. Hospitals Market, 2021 - 2033 (USD Million)
• 5.6. Clinical Laboratories
  • 5.6.1. Clinical Laboratories Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Precision Medicine Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2025 & 2033
• 6.2. Regional Market Dashboard
• 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 6.4. North America
  • 6.4.1. North America Precision Medicine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 6.4.2. U.S.
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Target Disease Prevalence
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Reimbursement Framework
    • 6.4.2.5. U.S. Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Canada
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Target Disease Prevalence
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. Reimbursement Framework
    • 6.4.3.5. Canada Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Mexico
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Target Disease Prevalence
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. Reimbursement Framework
    • 6.4.4.5. Mexico Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. Europe Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. UK
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Target Disease Prevalence
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Reimbursement Framework
    • 6.5.2.5. UK Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Germany
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Target Disease Prevalence
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. Reimbursement Framework
    • 6.5.3.5. Germany Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. France
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Target Disease Prevalence
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. Reimbursement Framework
    • 6.5.4.5. France Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. Italy
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Target Disease Prevalence
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. Reimbursement Framework
    • 6.5.5.5. Italy Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Spain
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Target Disease Prevalence
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Reimbursement Framework
    • 6.5.6.5. Spain Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Denmark
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Target Disease Prevalence
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Reimbursement Framework
    • 6.5.7.5. Denmark Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.8. Sweden
    • 6.5.8.1. Key Country Dynamics
    • 6.5.8.2. Target Disease Prevalence
    • 6.5.8.3. Regulatory Framework
    • 6.5.8.4. Reimbursement Framework
    • 6.5.8.5. Sweden Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.9. Norway
    • 6.5.9.1. Key Country Dynamics
    • 6.5.9.2. Target Disease Prevalence
    • 6.5.9.3. Regulatory Framework
    • 6.5.9.4. Reimbursement Framework
    • 6.5.9.5. Norway Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Asia Pacific Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Japan
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Target Disease Prevalence
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Reimbursement Framework
    • 6.6.2.5. Japan Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. China
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Target Disease Prevalence
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Reimbursement Framework
    • 6.6.3.5. China Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.4. India
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Target Disease Prevalence
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Reimbursement Framework
    • 6.6.4.5. India Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.5. Australia
    • 6.6.5.1. Key Country Dynamics
    • 6.6.5.2. Target Disease Prevalence
    • 6.6.5.3. Regulatory Framework
    • 6.6.5.4. Reimbursement Framework
    • 6.6.5.5. Australia Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.6. South Korea
    • 6.6.6.1. Key Country Dynamics
    • 6.6.6.2. Target Disease Prevalence
    • 6.6.6.3. Regulatory Framework
    • 6.6.6.4. Reimbursement Framework
    • 6.6.6.5. South Korea Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6.7. Thailand
    • 6.6.7.1. Key Country Dynamics
    • 6.6.7.2. Target Disease Prevalence
    • 6.6.7.3. Regulatory Framework
    • 6.6.7.4. Reimbursement Framework
    • 6.6.7.5. Thailand Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Latin America Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. Brazil
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Target Disease Prevalence
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. Reimbursement Framework
    • 6.7.2.5. Brazil Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Argentina
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Target Disease Prevalence
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Reimbursement Framework
    • 6.7.3.5. Argentina Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Middle East & Africa
  • 6.8.1. Middle East & Africa Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.2. South Africa
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Target Disease Prevalence
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Reimbursement Framework
    • 6.8.2.5. South Africa Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.3. Saudi Arabia
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Target Disease Prevalence
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. Reimbursement Framework
    • 6.8.3.5. Saudi Arabia Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.4. UAE
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Target Disease Prevalence
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. Reimbursement Framework
    • 6.8.4.5. UAE Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8.5. Kuwait
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Target Disease Prevalence
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Reimbursement Framework
    • 6.8.5.5. Kuwait Precision Medicine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Participant Overview
• 7.2. Company Market Position Analysis
• 7.3. Company Categorization
• 7.4. Strategy Mapping
• 7.5. Company Profiles/Listing
  • 7.5.1. F. Hoffmann-La Roche Ltd
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Siemens
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. Janssen Global Services, LLC
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. Illumina, Inc.
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Quest Diagnostics Incorporated
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. 23andMe, Inc.
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. NeoDiagnostix
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Myriad Genetics
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Medtronic
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives
  • 7.5.10. GE Healthcare
    • 7.5.10.1. Overview
    • 7.5.10.2. Financial Performance
    • 7.5.10.3. Product Benchmarking
    • 7.5.10.4. Strategic Initiatives
  • 7.5.11. Abbott
    • 7.5.11.1. Overview
    • 7.5.11.2. Financial Performance
    • 7.5.11.3. Product Benchmarking
    • 7.5.11.4. Strategic Initiatives
  • 7.5.12. QIAGEN
    • 7.5.12.1. Overview
    • 7.5.12.2. Financial Performance
    • 7.5.12.3. Product Benchmarking
    • 7.5.12.4. Strategic Initiatives